US-based data-driven clinical trials provider Medable and the University of Pennsylvania School of Medicine have partnered to accelerate patient enrolment and increase participant retention in the Light Treatment Effectiveness (LITE) trial.
The study evaluates home versus office-based narrowband ultraviolet B phototherapy versus other treatments to treat psoriasis.
Medable’s direct-to-patient app was chosen for the Phase IV pragmatic LITE study that will enrol 1,050 subjects across several clinical site locations.
University of Pennsylvania Perelman School of Medicine Dermatology and Epidemiology professor Dr Joel Gelfand said: “Medable’s technology solution ensures our patient and site facing apps integrate seamlessly into the busy schedules of our patients and researchers, leading to more complete and accurate data collection, as well as better patient enrolment and retention in our study.
“We needed a partner that had the technical sophistication and experience necessary to customise the LITE study app to the needs of our patients and researchers, while providing the inter-operability to connect clinicians, researchers, and patients across our different sites.”
This month, Medable announced that it is set to join the American Heart Association’s Center for Health Technology & Innovation Innovators Network to improve a patient-centric digital system that connects patients and researchers.
The company unveiled a telemedicine solution called Trial-Fit Telemedicine this June for clinical trials.
Medable CEO and founder Dr Michelle Longmire said: “As we continue to expand into the growing clinical trials landscape, we’re excited to collaborate with Penn Medicine, a leading academic centre on this important study in psoriasis.
“Through a patient-centric approach, we will accelerate enrolment, increase patient retention and connect clinicians and patients with our technology solutions.”
